Science & Enterprise subscription

Please share Science & Enterprise

RSS
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

3-D Models Devised to Simulate Patients’ Tumors

Gioeli lab group

A university lab is teaming up with a local biotechnology company to develop realistic models of tumors from individual cancer patients, enabling more personalized treatment options. . . . → Read More: 3-D Models Devised to Simulate Patients’ Tumors

Stem Cell Eye Implants Safe, Stop Visual Function Loss

Early results from a clinical trial show implants of replacement retina cells grown from stem cells are safe for people with a form of age-related macular degeneration, and at least stop the loss of visual function. . . . → Read More: Stem Cell Eye Implants Safe, Stop Visual Function Loss

Lilly, Cell Implants Start-Up Partner on Diabetes

Eli Lilly and Company is licensing a technology for implanting pancreatic beta cells in people with type 1 diabetes, from Sigilon Therapeutics Inc., an enterprise making implants of live cells to treat chronic diseases. . . . → Read More: Lilly, Cell Implants Start-Up Partner on Diabetes

New Company Acquires Off-the-Shelf T-Cell Cancer Therapies

A new enterprise is formed to develop treatments for cancer using donated T-cells from the immune system, rather than the patient’s own T-cells, engineered to attack cancer cells. . . . → Read More: New Company Acquires Off-the-Shelf T-Cell Cancer Therapies

Cough Suppressant Produced from Engineered Yeast Cells

A bioengineering group created a process for producing a cough suppressant in the lab, usually derived from opium poppies, but instead from genetically modified brewer’s yeast. . . . → Read More: Cough Suppressant Produced from Engineered Yeast Cells

Antibodies Licensed for Multi-Target Immunotherapies

MedImmune, the biologics subsidiary of drug maker AstraZeneca, is licensing antibodies from a biotechnology company for treatments that simultaneously address two or more cancer targets. . . . → Read More: Antibodies Licensed for Multi-Target Immunotherapies

Patent Awarded for Nanoparticle Drug, Cannabis Delivery

A delivery technology for therapeutic compounds in nanoscale natural oil particles received a U.S. patent, which the company owning the technology says can be applied to drugs, nutritional supplements, and cannabis-based treatments. . . . → Read More: Patent Awarded for Nanoparticle Drug, Cannabis Delivery

Novartis Licenses Biomaterial for Cancer Immunotherapy

Drug maker Novartis is licensing from a lab at Harvard University a biocompatible material designed to provide delivery of treatments that invoke the immune system to fight cancer. . . . → Read More: Novartis Licenses Biomaterial for Cancer Immunotherapy

Smartphone App, Device Shown to Measure Blood Pressure

A smartphone-based system and app were shown in a pilot study with human subjects to measure a person’s blood pressure with about the same accuracy as some cuff devices normally used to gauge blood pressure. . . . → Read More: Smartphone App, Device Shown to Measure Blood Pressure

Evotec Acquiring Sanofi Infectious Disease Portfolio

Drug discovery company Evotec AG is licensing 10 infectious disease R&D programs and their 100 employees from drug maker Sanofi, and opening new labs for this work in Lyon, France. . . . → Read More: Evotec Acquiring Sanofi Infectious Disease Portfolio